Article

D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes

Department of Medicine, George Washington University School of Medicine, Washington, D.C., USA.
Nutrition (Impact Factor: 3.05). 10/2008; 25(1):58-65. DOI: 10.1016/j.nut.2008.07.012
Source: PubMed

ABSTRACT Certain D2 dopamine receptor Taq 1A genotypes (A1A1, A1A2) have been associated with obesity and substance abuse. We hypothesized that their presence would be associated with reduced efficacy of dietary interventions in individuals with type 2 diabetes.
In the course of a randomized clinical trial in an outpatient research center in which 93 adults with type 2 diabetes were assigned to a low-fat vegan diet or a diet following 2003 American Diabetes Association guidelines for 74 wk, Taq 1A genotype was determined. Nutrient intake, body weight, and hemoglobin A1c (A1c) were measured over 74 wk.
The A1 allele was highly prevalent, occurring in 47% of white participants (n = 49), which was significantly higher than the 29% prevalence previously reported in non-diabetic whites (P = 0.01). The A1 allele was found in 55% of black participants (n = 44). Black participants with A1(+) genotypes had significantly greater mean body weight (11.2 kg heavier, P = 0.05) and greater intake of fat (P = 0.002), saturated fat (P = 0.01), and cholesterol (P = 0.02) compared with A2A2 (A1(-)) individuals; dietary changes during the study did not favor one genotype group. Among whites, baseline anthropometric and nutrient differences between gene groups were small. However, among whites in the vegan group, A1(+) individuals reduced fat intake (P = 0.04) and A1c (P = 0.01) significantly less than did A1(-) individuals.
The A1 allele appears to be highly prevalent among individuals with type 2 diabetes. Potential influences on diet, weight, and glycemic control merit further exploration.

Download full-text

Full-text

Available from: Gabrielle Turner-McGrievy, Jul 08, 2015
0 Followers
 · 
149 Views
  • Source
    • "Additionally, dopamine plays a key role in the central regulation of insulin action: bromocriptine, a DRD2 agonist, significantly reduces HbA1c and fasting plasma glucose in individuals with type 2 diabetes (Pijl et al., 2000). Barnard et al. (2009) found that, the A1 + genotypes were highly prevalent among type 2 diabetic patients. In this study, Taq1A1/A1 genotye of the DRD2 gene was associated with hyperinsulinemia in adolescent obese subjects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims: The dopaminergic and endocannabinoid systems are involved in regulation of feeding behavior. The aim of the study is to examine the possible relation between polymorphisms of the dopamine D2 receptor (DRD2) and cannabinoid receptor-1 (CNR1) genes and childhood obesity. Methods: A hundred obese children and 100 healthy controls were analyzed for DRD2 Taq1A and Taq1B and CNR1 1359G/A polymorphisms. Genotyping was performed by polymerase chain reaction and restriction fragment length polymorphism. Results: There were no statistically significant differences in DRD2 Taq1A and DRD2 Taq1B genotypes or allelic frequencies between obese children and controls (p>0.05). In patients with Taq1B2 allele, morbid obesity was less frequent (p=0.010). The frequency of the A allele of CNR1 1359G/A polymorphism was significantly higher in obese children than in controls (21.0% vs. 13.0%, p=0.0166). The frequency of genotypes AG and GG of the CNR1 1359G/A SNP was different between obese children and control subjects (for AG: 34.0% vs. 22.0%, p=0.0294; for GG: 62.0% vs. 76.0%, p=0.0162, respectively). Conclusions: No significant difference was found between genotypes and alleles of DRD2 Taq1A and DRD2 Taq1B polymorphism in patients and controls, while the CNR1 receptor 1359G/A polymorphism and the presence of the A allele may be one risk factor for susceptibility to obesity.
    Genetic Testing and Molecular Biomarkers 10/2012; DOI:10.1089/gtmb.2012.0244 · 1.15 Impact Factor
  • Source
    • "In contrast , chronic food restriction showed greater striatal D2R binding relative to ad libitum fed rats [35] [36] [37]. Genetic studies, although not always consistent, have reported that individuals carrying the Taq I A1 allele of the D2R gene, which was associated with decrease in D2R in striatum by some investigators, are more vulnerable to addictive behaviors such as compulsive food intake and are more likely to be obese [38] [39]. Leptin receptors are also present in the ventrotegmental area (VTA) and leptin targets dopaminergic and gammaaminobutyric acid neurons in this region critical to brain reward circuits, inducing phosphorylation of signal transducer and activator of transcription. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a chronic and disabling mental illness affecting millions of people worldwide. A greater proportion of people with schizophrenia tends to be overweight. Antipsychotic medications have been considered the primary risk factor for obesity in schizophrenia, although the mechanisms by which they increase weight and produce metabolic disturbances are unclear. Several lines of research indicate that leptin could be a good candidate involved in pathways linking antipsychotic treatment and weight gain. Leptin is a circulating hormone released by adipocytes in response to increased fat deposition to regulate body weight, acting through receptors in the hypothalamus. In this work, we reviewed preclinical, clinical, and genetic data in order to infer the potential role played by leptin in antipsychotic-induced weight gain considering two main hypotheses: (1) leptin is an epiphenomenon of weight gain; (2) leptin is a consequence of antipsychotic-induced "leptin-resistance status," causing weight gain.
    Journal of obesity 03/2012; 2012:572848. DOI:10.1155/2012/572848
  • Source
    • "Specifically, we observed an association between DRD2 genotype and greater reported intake of high-calorie nonsweet foods in males. This finding is consistent with laboratory-based studies and studies with clinical samples that show associations with the DRD2 Taq1 A1 variant and consumption of carbohydrates (Noble, 2000), energy (Epstein et al., 2007), and fat intake (Barnard, et al., 2009). In females, we observed that those with the SLC6A3 10/10 genotype reported greater consumption of high-calorie sweet foods. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression and variation in dopamine related genes have both independently been associated with food consumption. Depressive symptoms could synergistically interact with genetic variation to influence food intake. We examined the interaction between high depressive symptoms and functional polymorphisms of dopamine transporter (SLC6A3), monoamine oxidase A (MAOA), dopamine receptor D2 (DRD2) and dopamine receptor D4 (DRD4) on intake of high-calorie sweet, high-calorie non-sweet, and low-calorie foods in the National Longitudinal Study of Adolescent Health (Add Health). Multivariate linear regression analyses were used to examine main effects of gene and depression symptoms and their interaction (genotype-by-high depression symptoms) on food categories. Applying a false discovery rate criterion for multiple comparisons indicated a statistically significant interaction for females with high depressive symptoms and the SLC6A3 gene, such that those with the SLC6A3 10/10 allele reported greater intake of high-calorie sweet foods than their counterparts high in depressive symptoms with the SLC6A3 any 9 allele (LS mean 10/10 allele=2.5, SE=.13; LS mean any 9 allele=1.8, SE=.13, p<.05). These findings highlight that the relationship between depression and food intake may vary as a function of genetic polymorphism. Further research is needed to confirm these findings.
    Appetite 06/2011; 57(2):339-48. DOI:10.1016/j.appet.2011.05.325 · 2.69 Impact Factor